Understanding GLP-1 Receptor Agonists

Describe how the pancreas, liver, muscle, adipose tissue, gut, and brain regulate fasting and post-meal blood glucose.

Explain how insulin resistance and pancreatic beta-cell dysfunction contribute to the progression of type 2 diabetes.

Explain how neuroendocrine signals regulate hunger, satiety, energy balance, and adaptation to weight loss.

Trace the gut–brain–pancreas signalling sequence that follows a meal.

Explain the secretion, receptor signalling, physiological actions, and degradation of native GLP-1.

Explain how pharmacological GLP-1 receptor agonism affects glucose regulation, appetite, gastric emptying, and body weight.

Compare the mechanisms of GLP-1 receptor agonists with dual GIP/GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors, and insulin.

Classify major incretin-based medicines by molecule, receptor profile, route, dosing frequency, and principal approved indication.

Explain how formulation and pharmacokinetic differences influence dosing cadence and between-visit monitoring needs.

Explain the clinical rationale for gradual dose escalation of GLP-1–based therapies.

Distinguish regulatory approval, an on-label indication, an off-label use, and guideline-supported practice.

Interpret HbA1c, time-in-range, and body-weight outcomes reported in trials of GLP-1–based therapies.

Interpret cardiovascular and kidney outcomes reported in trials of GLP-1–based therapies.

Appraise whether a GLP-1 trial's population, comparator, duration, attrition, and sponsorship affect its relevance to real-world care.

Map the clinician-led assessment process that precedes initiation of a GLP-1–based therapy.

Identify the baseline clinical, medication, behavioural, and access data needed for a structured GLP-1 programme.

Explain the expectations that should be established through shared decision-making before treatment begins.

Represent initiation and dose escalation as states in a clinician-approved care pathway.

Select the symptom, weight, glycaemic, laboratory, medication-use, and adherence domains that a care programme may monitor.

Distinguish inadequate response, expected plateau, maintenance, treatment interruption, and clinician-directed discontinuation.

Map clinician-approved workflows for switching therapy, restarting after interruption, and responding to supply shortages.

Characterise the typical timing, severity, and course of common gastrointestinal adverse effects of GLP-1–based therapies.

Explain the nutrition, hydration, and lean-mass risks that can accompany reduced intake and rapid weight loss.

Identify when concomitant insulin or sulfonylurea use increases the risk of hypoglycaemia.

Recognise patterns that may indicate dehydration or acute kidney injury during GLP-1–based treatment.

Recognise warning signs associated with pancreatitis, gallbladder disease, severe gastrointestinal complications, and serious allergic reactions.

Locate and interpret label-specific contraindications, precautions, and clinically relevant medication interactions.

Explain why pregnancy planning, breastfeeding, surgery, anaesthesia, and procedures require clinician-led treatment decisions.

Map the informational, practical, and emotional needs that arise across a patient's GLP-1 treatment journey.

Write a health-literacy-sensitive explanation of GLP-1 treatment that sets realistic expectations without promotional overstatement.

Identify adherence and persistence barriers related to side effects, administration, cost, access, stigma, and medicine supply.

Select patient-reported questions and measures appropriate to each phase of a structured GLP-1 programme.

Choose among SMS, WhatsApp, USSD, and voice according to accessibility, privacy, interaction complexity, and urgency.

Design a phase-based contact cadence that balances continuity, personalisation, and communication fatigue.

Translate a clinician-approved care protocol into observable signals that a continuity product can collect.

Classify a detected signal as suitable for automated guidance, coordinator judgement, clinician review, or emergency direction.

Combine symptom severity, timing, trend, medication context, and patient vulnerability into a Decision Window.

Design escalation rules for non-response, incomplete data, contradictory answers, and loss to follow-up.

Apply severity, deduplication, suppression, prioritisation, and routing rules to reduce alert fatigue.

Test a Decision Window workflow against routine cases, edge cases, and channel or integration failures.

Define a minimum longitudinal data model for enrolment, treatment state, check-ins, signals, decisions, interventions, and outcomes.

Represent Holdline's Enroll, Trigger, Hold, Prove, Exchange, and Learn loop as auditable events and state transitions.

Construct an audit record containing actor, timestamp, source input, decision, action, rationale, outcome, and provenance.

Map core continuity data to relevant HL7 FHIR resources for exchange with clinical systems.

Design a minimum-necessary exchange pattern among Holdline, provider systems, pharmacies, laboratories, and payers.

Select leading and lagging measures of continuity quality, workflow performance, patient outcomes, safety, and equity.

Distinguish administrative automation, patient communication, clinical decision support, and regulated clinical functionality in a continuity product.

Define accountability, approval, supervision, incident response, and change-control roles for a provider-governed GLP-1 programme.

Compare consent, health-data privacy, retention, and electronic-communication requirements across Kenya, South Africa, the UK, and the US.

Build a jurisdictional checklist for assessing relevant oversight by health, medicines, software, data-protection, and communications regulators.

Design the capture, clinical handoff, documentation, and reporting pathway for suspected adverse drug events.

Assess an AI-enabled workflow for explainability, bias, human oversight, performance drift, and post-deployment monitoring.

Map the incentives, risks, workflow needs, and evidence expectations of patients, providers, payers, pharmaceutical companies, pharmacies, and regulators.

Compare GLP-1 access, reimbursement, and programme-financing pathways in Kenya and East Africa, South Africa, the UK, and the US.

Design a Holdline pilot evaluation covering safety, operational performance, engagement, clinical proxies, economics, and equity.

Assemble the course artifacts into a provider-centred GLP-1 continuity product blueprint with explicit clinical boundaries and market assumptions.